ArticleSeminars in arthritis and rheumatism2018
Concurrence of rheumatoid arthritis and calcium pyrophosphate deposition disease: A case collection and review of the literature.
Article in Seminars in arthritis and rheumatism, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Expert Perspective: Treatment of Patients With Calcium Pyrophosphate Deposition Disease: Where Do We Begin and Where Are We Going?Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Characteristics and long-term outcomes of patients with rheumatoid arthritis and concurrent calcium pyrophosphate deposition disease.Seminars in arthritis and rheumatism · 2026Article
- A Case of Pseudogout in an Adolescent on Isotretinoin.Case reports in rheumatology · 2026Article
- Crowned Dens Syndrome associated with rheumatoid arthritis: A case report of two patients with a systematic literature review.Caspian journal of internal medicine · 2026Article
- Calcium Pyrophosphate Crystal Deposition: Insights to Risks Factors and Associated Conditions.Current rheumatology reports · 2024Review
- [First classification criteria for diseases caused by calcium pyrophosphate deposition (CPPD)-Translation, explanation and assessment].Zeitschrift fur Rheumatologie · 2024Article
- Article
- The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease.Annals of the rheumatic diseases · 2023Article
- The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease.Arthritis & rheumatology (Hoboken, N.J.) · 2023Article
- Article
- Usefulness of ultrasound in the diagnosis of crystal deposition diseases.European journal of rheumatology · 2022Article
- A critical review of the available evidence on the diagnosis and clinical features of CPPD: do we really need imaging?Clinical rheumatology · 2021Review
- [A patient with inflammatory arthralgia, paraesthesia and atrial fibrillation].Zeitschrift fur Rheumatologie · 2020Article
- [Chondrocalcinosis: idiopathic or manifestation of rare metabolic diseases?]Der Orthopade · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
objectiveCalcium pyrophosphate deposition disease (CPDD) is arthritis caused by calcium pyrophosphate (CPP) crystal deposition in joints. It is commonly associated with aging as well as a handful of metabolic syndromes. Recent epidemiologic studies suggest a positive association of CPDD and rheumatoid arthritis (RA). Yet how these diseases are related remains unclear. We set out to describe 21 well-characterized patients with both diagnoses.
methodsMedical records of patients with both RA and CPDD identified at a single academic practice site were reviewed for age, gender, age of CPDD and RA onset, disease duration, joint involvement, and lab values including rheumatoid factor (RF), cyclic citrullinated peptide antibody (CCP), iron studies, and parathyroid hormone and calcium levels.
resultsThe mean age of CPDD onset was 69.5 ± 11.4 years, with a mean RA age onset of 53.9 ± 16 years, demonstrating a mean lag of 13.4 ± 10.9 years between diagnoses. The majority of RA patients were diagnosed with CPDD based on the presence of radiographic chondrocalcinosis (15/21). The most commonly involved joint was the knee, followed by the wrist, hip, and shoulder.
conclusionsThese data show that the diagnosis of RA often precedes the diagnosis of CPDD. This asynchronous presentation taken together with the classic age of onset for CPDD and typical pattern of joint involvement supports the hypothesis that CPDD develops in RA patients through similar processes as those that cause the idiopathic forms of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.